Ovarian low malignant potential tumour – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:54 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Ovarian low malignant potential tumour – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of catequentinib (AL3818) combined with platinum chemotherapy for patients with recurrent or metastatic ovarian, fallopian tube, or primary peritoneal cancer https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-adding-catequentinib-to-chemotherapy-for-patients-with-recurrent-or-metastatic-ovarian-fallopian-or-primary-peritoneal-cancer/ Wed, 29 Apr 2026 14:57:48 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-adding-catequentinib-to-chemotherapy-for-patients-with-recurrent-or-metastatic-ovarian-fallopian-or-primary-peritoneal-cancer/ This clinical trial studies the effectiveness of adding catequentinib (also known as AL3818) to standard platinum-based chemotherapy in treating platinum-resistant recurrent or metastatic ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Catequentinib is a type of drug called a receptor tyrosine kinase inhibitor, which works by blocking certain proteins that help cancer cells grow.

The main purpose of this research is to determine if adding catequentinib to standard chemotherapy improves how long patients live without their cancer getting worse. The medication is taken by mouth in the form of capsules, with different dose levels being tested. During the study, participants will receive either catequentinib combined with standard chemotherapy or standard chemotherapy alone.

The study will track how well tumors respond to treatment, how long any improvements last, and how long patients survive overall. Doctors will use special imaging tests called CT or MRI scans to measure if tumors are shrinking or growing. The total duration of treatment may continue for up to 336 days, depending on how well patients respond and tolerate the medication.

]]>